Trial Profile
A Pilot Window-of-opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 26 Apr 2023 Planned primary completion date changed from 20 Dec 2022 to 20 Dec 2025.
- 27 Apr 2020 Planned End Date changed from 1 Sep 2018 to 20 Dec 2025.
- 27 Apr 2020 Planned primary completion date changed from 1 Mar 2018 to 20 Dec 2022.